Metal Complex Analgesic Composition for Reduced GI Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pain treatments, such as NSAIDs, morphine-based drugs, anticonvulsants, and antidepressants, have significant limitations, including analgesic ceiling effects, side effects, and inadequate long-term pain management, particularly for chronic pain.
Innovation Solution
Development of a metal complex drug composition comprising transition metal ions (Zn2+, Co2+, Pt2+, VO(IV), or MoO2(VI)) coordinated with alpha-hydroxypyranone or alpha-hydroxypyridone ligands, which form unsaturated metal-containing rings, offering a novel approach to pain relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NSAIDs are used for pain treatment, then analgesic effect is achieved, but analgesic ceiling effect and gastrointestinal side effects occur
Solution Approach 1:
The patent changes the chemical structure parameters by introducing metal complexes with specific coordination geometries and electronic configurations. The metal center (e.g., Fe, Co, Ni, Cu, Zn) and ligand combination creates a novel pharmacological profile that achieves analgesic effects without the gastrointestinal side effects characteristic of traditional NSAIDs.
Solution Approach 2:
The invention uses composite structures consisting of metal ions coordinated with organic ligands (β-diketonates, carboxylates, or their derivatives). This composite approach combines the advantages of metal-based pharmacology with organic molecular recognition, producing analgesic effects that bypass the limitations of conventional NSAIDs.
2Reliability
If morphine-based drugs are used for pain treatment, then strong analgesic effect is achieved, but addiction and respiratory depression occur
Solution Approach 1:
The patent fundamentally changes the pharmacological parameter by using metal complexes instead of opioid molecules. The metal-ligand coordination sphere creates a novel mechanism of action that provides strong analgesic effects through non-opioid pathways, eliminating the risk of addiction and respiratory depression associated with morphine-based drugs.
Solution Approach 2:
The metal complex acts as an intermediary substance that mediates pain relief through a different biochemical pathway. Instead of binding to opioid receptors like morphine, the metal complex interacts with pain signaling pathways through its unique electronic and steric properties, providing analgesia without the harmful side effects.
3Duration of action of moving object
If traditional analgesic drugs are used, then short-term pain relief is achieved, but long-term pain management is inadequate
Solution Approach 1:
The patent introduces dynamic adaptability through the metal complex's ability to undergo coordination chemistry reactions in vivo. The metal center can dynamically exchange ligands and interact with biological targets, providing sustained analgesic effects that adapt to the body's needs over time, thereby improving long-term pain management.
Solution Approach 2:
The metal complex maintains continuous therapeutic action through its stable coordination sphere and persistent biological activity. The metal-ligand complex resists degradation and maintains its analgesic properties over extended periods, providing continuous pain relief that addresses the inadequacy of traditional short-acting analgesics for chronic pain conditions.
Data Source
AI summary
A drug composition having the structure of formula I for the treatment of pain is provided. The drug can be given to an animal via oral, transdermal, rectal, intravenous, subcutaneous, sublingual or intraperitoneal administration, etc., thereby exerting an analgesic effect. The active components of the drug are convenient to prepare and easy to identify, and are structurally different from those of all other existing analgesic drugs, thus forming a novel class of effective analgesic compounds.